Cat.No. | Name | Information |
---|---|---|
M3835 | Alirocumab | Alirocumab is a humanized IgG1 PCSK9 monoclonal antibody that can be used in the study of hypercholesterolemia. |
M11343 | Pinostrobin | Pinostrobin is a flavonoid found in many plants and has antioxidant, anti-inflammatory, anticancer and neuroprotective properties. Pinostrobin is an effective INHIBITOR of PCSK9, which can inhibit the catalytic activity of PCSK9. Pinostrobin is a promising agent for cholesterol regulation and lipid management. |
M11162 | Pep2-8 | Pep2-8 is a PCSK9 inhibitor, of which KD The value is 0.7 μM,IC50 The value is 1.4 μM. |
M10699 | SBC-115337 | SBC-115337 is a potent benzofuran compound that is an inhibitor of PCSK9,IC50 The value is 0.5 μM. |
M9966 | PF-06446846 hydrochloride | PF-06446846 hydrochloride is a selective orally active PCSK9 inhibitor that appears to act by causing the ribosome to stall when synthesizing PCSK9. |
M9867 | SBC-110736 | SBC-110736 is a novel inhibitor of proprotein convertase subtilisin kexin type 9 (PCSK9). |
M7542 | SBC-115076 | Sbc-115076 is an effective inhibitor of the preprotein invertase Bacillus subtilis proteinase/Kexin 9 (PCSK9). PCSK9 is a preprotein invertase that plays an important role in LDL receptor metabolism. |
M6251 | R-IMPP | R-impp (PF-00932239) is an anti-secreting inhibitor of PCSK9 (IC50=4.8 μM), which can inhibit PCSK9 protein translation by targeting the ribosomes at the time of 80S. |
M4247 | Schizandrol-B | Schisantherin B (Gomisin-B; Wuweizi ester-B; Schisantherin-B) is a lignan from Schisandra chinensis that promotes liver enlargement in mice through activation of the PXR and YAP pathways and inhibits PCSK9 protein expression with an IC50 value of 1.10 μM. |
M1595 | Evolocumab | Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). |
M45130 | NNC0385-0434 | NNC0385-0434 is an orally active peptide small molecule PCSK9 inhibitor for atherosclerosis-related studies. |
M45129 | CiVi-008 | CiVi-008 is an orally active PCSK9 antisense oligonucleotide (ASO) inhibitor for studies related to disorders of lipid metabolism. |
M45128 | CiVi-007 | CiVi-007 is an antisense oligonucleotide (ASO) polymerized with N-acetylglucosamine that targets PCSK9 and can be used in studies related to hypercholesterolemia. |
M45125 | AZD-8233 | AZD-8233 is an orally active, antisense oligonucleotide (ASO) targeting PCSK9 that targets and inhibits the translation and protein synthesis of PCSK9 mRNA in hepatocytes and reduces circulating LDL-C levels. It can be used in studies related to hypercholesterolemia. |
M40600 | Ebronucimab | Ebronucimab is a monoclonal antibody to PCSK9 that can be used in studies related to hypercholesterolemia. |
M28735 | PF-06446846 | PF-06446846 is an orally active proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. PF-06446846 directly and selectively inhibits translation of PCSK9 by stalling the 80S ribosome in the proximity of codon region. |
M25402 | Enlicitide chloride | Enlicitide (MK-0616) chloride is an oral PCSK9 macrocyclic peptide inhibitor. |
M25092 | Recaticimab | Recaticimab (SHR-1209) is a humanized monoclonal antibody that inhibits PCSK9. Receticimab mediates the degradation of PCSK9 by binding to PCSK9, increasing the level of low-density lipoprotein (LDL) receptors on the surface of hepatocytes, reducing the level of LDL in plasma, and achieving the goal of lowering blood lipids. Recaticimab has potential application in hypercholesterolemia. |
M25040 | Lerodalcibep | Lerodalcibep (LIB003) is a recombinant fusion protein of a PCSK9-binding domain (adnectin) and human serum albumin. Lerodalcibep is a Lipid-lowering agent. Lerodalcibep can be used for the research of hypercholesterolemia and cardiovascular diseases. |
M24997 | Tafolecimab | Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.